Glenmark Pharmaceuticals rolls out heart failure treatment Sacu V in India

Glenmark Pharmaceuticals said that it has rolled out the sacubitril + valsartan tablets for the treatment of heart failure in India under the brand name Sacu V.

According to Glenmark Pharmaceuticals, Sacu V should be taken daily two times under doctor’s prescription.

The approved indication of sacubitril + valsartan tablets is for reduction of the risk of cardiovascular related deaths and hospitalizations for patients with chronic heart failure with reduced ejection fraction.

Alok Malik — Glenmark Pharmaceuticals EVP and India Formulations Business Head said: “Heart failure is growing in India at an alarming rate; its prevalence is about 1% and affects around 8‐10 million individuals.

“With the launch of Sacu V, we are proud to bring to the patients an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and to improve symptoms associated with heart failure with reduced ejection fraction (HFrEF).”

The cost of Sacu V is INR 19 per tablet for a 50mg dose (sacubitril 24mg + valsartan 26mg), INR 35 per tablet for a 100mg dose (sacubitril 49mg + valsartan 51mg), and INR 45 per tablet for a 200mg dose (sacubitril 97mg + valsartan 103mg).